For a 5‑year‑old child who has received four doses of diphtheria‑tetanus‑acellular pertussis (DTaP) vaccine and three doses of inactivated poliovirus (IPV) vaccine, which vaccines are indicated now and can the child receive the combination vaccine Kinrix (DTaP‑IPV) as his fifth DTaP and fourth IPV dose?

Vaccines for a 5-Year-Old and Kinrix Eligibility

No, this child cannot receive Kinrix because the FDA-approved indication specifically requires that the first 3 DTaP doses were Infanrix and/or Pediarix AND the fourth dose was Infanrix—you have not specified which DTaP products were used for this child's previous doses. 1

Understanding Kinrix Licensing Requirements

The FDA label for Kinrix is very specific and restrictive about which children can receive it:

• Kinrix is only approved as the fifth DTaP dose and fourth IPV dose in children aged 4-6 years 1
• Critical requirement: The child's vaccination history must show:
  • First 3 DTaP doses: Infanrix and/or Pediarix only
  • Fourth DTaP dose: Infanrix only 2, 1

Your child's situation:

• Has received 4 DTaP doses (needs 5th)
• Has received 3 IPV doses (needs 4th)
• Age 5 years (appropriate age range)
• BUT: You haven't specified which DTaP products were used

Alternative Vaccine Options

If the previous DTaP doses were NOT the specific GSK products (Infanrix/Pediarix), consider:

Quadracel (Sanofi Pasteur)

• Licensed for the fifth DTaP dose and fourth IPV dose
• Requirement: Previous 4 doses must have been Pentacel and/or Daptacel 2
• Age range: 4-6 years

Separate DTaP + IPV Administration

• Give standalone DTaP (Infanrix or Daptacel) plus standalone IPV
• This approach works regardless of which products were used previously
• Requires two injections instead of one

Routine Vaccines Needed at Age 5

According to ACIP recommendations, a 5-year-old typically needs 2:

1. Fifth DTaP dose (if not yet received)
2. Fourth IPV dose (if not yet received)
3. Second MMR dose (if not yet received)
4. Second varicella dose (if not yet received)
5. Annual influenza vaccine

Critical Action Steps

Before administering Kinrix, you must:

1. Review the child's immunization record to identify the specific DTaP vaccine products used for doses 1-4
2. Verify the IPV doses received (should have 3 documented)
3. Match the vaccine history to the appropriate combination vaccine's FDA-approved indication

Common pitfall: Assuming all DTaP vaccines are interchangeable for combination vaccine eligibility—they are not. The FDA licensing for Kinrix and Quadracel is product-specific, not class-specific 2, 1.

Clinical Reasoning

The restrictive licensing of these combination vaccines stems from the clinical trial designs used for FDA approval. Kinrix was studied specifically in children who received GSK products (Infanrix/Pediarix) for their primary series 2, 3, 4. Using it outside this indication is off-label and lacks the immunogenicity and safety data that support the approved use.

If the vaccine history is unknown or mixed products were used, the safest approach is separate DTaP and IPV administration, which has no product-specific restrictions and ensures adequate protection against all diseases 2.